Content Library for
Neuroscience,Cannabinoids &
Tryptamines Research

When we find interesting articles and thought leadership that is relevant to synthetic biology, neuroscience, mental healthcare and the use of cannabinoids and psychedelics as therapeutics, we like to put it here.

Check Out our new White Paper on Advances in Cellular Agriculture for Neuroscience

The study characterized the subjective phenomena, interpretation, and persisting changes that people attribute to N,N-dimethyltryptamine-occasioned entity encounter experiences.

A third of Americans are showing signs of clinical anxiety or depression, Census Bureau data shows, the most definitive and alarming sign yet of the psychological toll exacted by the coronavirus pandemic.

In the last few years, new research has demonstrated the powerful potential for classical psychedelics, especially psilocybin (the active compound in “magic mushrooms”), to treat a range of mental health disorders, including depression, anxiety and addiction.

Putting it simply, synthetic biology is an engineering approach to biology. It involves the design and construction of biological parts to get them to do useful things inside cells.

Despite Covid-19, a crashing economy and formidable legal obstacles, a growing number of entrepreneurs and investors are betting that medicines derived from psychedelic drugs can become a real business and heal millions of people. 

Even before COVID-19 set off a global tsunami of anxiety and depression, psychedelic drugs were already showing exciting promise for treating these and other intractable mental health conditions.

PSYC, a new company formed by the holding company Global Trac Solutions Inc., is one of a handful of young companies and respected universities and research centers that are exploring the therapeutic potential of psychedelic drugs.
CB Therapeutics is able to cost efficiently produce at scale, many of these “minor” cannabinoids that have major therapeutic potential but exist in very small concentrations in the plant making them costly to extract.
CB Therapeutics is researching and developing molecules and compounds to advance Neuroscience and bring therapeutics to market to solve the opioid crisis, various addictions and mankind’s most challenging mental healthcare and social problems.
Psychedelics are not addictive. In fact if you take them every day, within three days they stop working. And people know that. Most people use psychedelics once or twice in their life recreationally because they don’t need to anymore, but they can be powerful in ways of changing the way people think about things like other drugs that are much more addictive.

More and more research is being done on the efficacy of psilocybin, MDMA, DMT and other tryptamine compounds and their analogs for the treatment of some of mankind’s greatest mental healthcare and end of life challenges. CB Therapeutics is working hard to produce the therapeutics needed for clinical trials to address these challenges.
Psilocybin has shown promise for conditions like depression. Now, researchers are asking if the psychedelic experience is absolutely necessary to treat mental health.

A patient with depression once described their condition as “being enclosed in the most narrow confined space imaginable, it was like a sack over my head.” Another said it was as if he was locked in a metal cage “from the shoulders up,” or in a “mental prison.”